Share on StockTwits

Alkermes Plc (NASDAQ:ALKS) Director Robert A. Breyer sold 5,000 shares of Alkermes Plc stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $42.53, for a total transaction of $212,650.00. Following the transaction, the director now directly owns 53,156 shares of the company’s stock, valued at approximately $2,260,725. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Shares of Alkermes Plc (NASDAQ:ALKS) traded up 1.03% during mid-day trading on Tuesday, hitting $43.25. The stock had a trading volume of 920,154 shares. Alkermes Plc has a 52 week low of $29.36 and a 52 week high of $54.25. The stock has a 50-day moving average of $47.49 and a 200-day moving average of $47.04. The company’s market cap is $6.307 billion.

Alkermes Plc (NASDAQ:ALKS) last released its earnings data on Thursday, July 31st. The company reported $0.11 earnings per share for the quarter, missing the analysts’ consensus estimate of $0.14 by $0.03. The company had revenue of $153.40 million for the quarter, compared to the consensus estimate of $146.91 million. During the same quarter last year, the company posted $0.30 earnings per share. Alkermes Plc’s revenue was up 10.7% compared to the same quarter last year. On average, analysts predict that Alkermes Plc will post $0.31 earnings per share for the current fiscal year.

Several analysts have recently commented on the stock. Analysts at Credit Suisse cut their price target on shares of Alkermes Plc from $57.00 to $56.00 in a research note on Friday. Separately, analysts at Mizuho cut their price target on shares of Alkermes Plc from $61.00 to $59.00 in a research note on Thursday, July 31st. They now have a “buy” rating on the stock. Finally, analysts at Zacks reiterated a “neutral” rating on shares of Alkermes Plc in a research note on Friday, July 11th. They now have a $50.00 price target on the stock. One research analyst has rated the stock with a sell rating, three have given a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $49.13.

Alkermes Public Limited Company is an integrated, global biopharmaceutical company. The Company has a portfolio of more than 20 commercial drug products and a clinical pipeline of product candidates that address central nervous system (NASDAQ:ALKS) disorders such as addiction, schizophrenia and depression.

Receive News & Ratings for Alkermes Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes Plc and related companies with Analyst Ratings Network's FREE daily email newsletter.